ACE and cardiomyopathy: Such imprecision is also evident in the descriptors for DMD drugs that modulate the renin-angiotensin system (e.g., ACE blockade and ARBs), where their potential as high-prospect drug candidates is linked to more recent discoveries of their effect on skeletal muscle pathophysiology, beyond their initial indications as components of standard treatment cocktails for DMD-associated cardiomyopathy.